Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nodules With Ground-glass Opacity

Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nodules With Ground-glass Opacity: A Prospective Randomized Controlled Trial

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07389889

Enrollment

116

Registered

2026-02-05

Start date

2026-02-01

Completion date

2029-02-01

Last updated

2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Nodules, Ground-glass Opacity

Keywords

ggo

Brief summary

1. To compare the precision of robot-guided microwave ablation and CT-guided microwave ablation in the treatment of ground-glass nodules. 2. To evaluate the safety of robot-assisted microwave ablation and CT-guided microwave ablation in the treatment of ground-glass nodules. 3. Explore the application potential of robot navigation microwave ablation technology in the treatment of pulmonary nodules.

Interventions

PROCEDURERobot

Microwave ablation guided by Robot or CT

PROCEDURECT scan

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

1. Aged 18 to 85 years 2. Nodules measuring 3-30mm with ground-glass opacities constituting ≥75% of the lesion 3. Preoperative clinical evaluation confirming no hilar or mediastinal lymph node metastasis and no distant metastasis 4. Patients diagnosed as stage IA primary peripheral lung cancer according to the UICC 8th TNM staging system, and with one of the following conditions: (i) cannot undergo surgical resection due to poor cardiopulmonary function or advanced age (ii) refusing or unwilling to undergo surgical resection (iii) with newly developed or residual pulmonary nodules after early-stage primary lung cancer surgery (iv) with unilateral lung disease who cannot undergo unilateral surgical resection (v)with multiple primary lung cancers unsuitable for surgical resection 5. Preoperative ECOG physical status score is 0/1 6. ASA score is I-III 7. Patients voluntarily participate in this study and sign the informed consent form

Exclusion criteria

1. Smoking cessation duration \<2 weeks 2. Lesions adjacent to pulmonary artery-vein main trunks 3. Lesions near the hilum or adjacent to lobar bronchi 4. Pregnancy or lactation status 5. Severe mental disorders 6. History of other malignancies within 5 years 7. Unstable angina or myocardial infarction within 6 months with coronary angiography showing severe stenosis of major coronary branches 8. Cerebral infarction or hemorrhage within 6 months 9. Continuous systemic corticosteroid therapy within 1 month 10. Patients or their authorized persons who do not wish to comply with the study protocol 11. Patients with other investigator-assessed ineligibility for the trial

Design outcomes

Primary

Measure	Time frame	Description
Accuracy of puncture	24 month	The proportion of patients who are successfully punctured to the target pulmonary nodule on the first attempt of puncture among all patients; whether the puncture is successful is validated by CT scan.

Contacts

CONTACTShuliang Zhang

670627941@qq.com+86 15806024509

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026